AHPI:NSD-Allied Healthcare Products Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 4.29

Change

+0.10 (+2.39)%

Market Cap

USD 0.02B

Volume

0.13M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Allied Healthcare Products Inc (AHPI) Stock Analysis:
Based on the Allied Healthcare Products Inc stock forecasts from 0 analysts, the average analyst target price for Allied Healthcare Products Inc is not available over the next 12 months. Allied Healthcare Products Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Allied Healthcare Products Inc is Slightly Bearish, which is based on 4 positive signals and 5 negative signals. At the last closing, Allied Healthcare Products Inc’s stock price was USD 4.29. Allied Healthcare Products Inc’s stock price has changed by -0.76% over the past week, -1.51% over the past month and -32.12% over the last year.

No recent analyst target price found for Allied Healthcare Products Inc
No recent average analyst rating found for Allied Healthcare Products Inc

About

Allied Healthcare Products, Inc. manufactures and markets respiratory products for use in the health care industry in a range of hospitals and alternate site settings worldwide. The company offers respiratory care/anesthesia products, including air compressors, calibration equipm ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-19 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DXCM DexCom Inc

+5.36 (+1.25%)

USD43.36B 84.37 117.62
ALGN Align Technology Inc

+8.03 (+1.64%)

USD41.37B 56.55 48.05
PODD Insulet Corporation

+0.92 (+0.39%)

USD16.15B 2,208.27 199.97
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
ABMD Abiomed Inc

+9.64 (+3.30%)

USD13.70B 92.48 46.15
BRKR Bruker Corporation

+0.08 (+0.12%)

USD10.73B 39.93 25.78
TNDM Tandem Diabetes Care Inc

+7.60 (+6.54%)

USD7.67B 356.22 187.52
SWAV ShockWave Medical Inc

-11.24 (-7.20%)

USD5.90B N/A N/A
IART Integra LifeSciences Holdings ..

-0.23 (-0.34%)

USD5.83B 27.08 17.89
LIVN LivaNova PLC

-0.53 (-0.63%)

USD4.51B 77.40 N/A

ETFs Containing AHPI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -26.29% 9% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.29% 9% F 8% F
Trailing 12 Months  
Capital Gain -32.12% 46% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -32.12% 46% F 31% F
Trailing 5 Years  
Capital Gain 104.29% 73% C 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 104.29% 73% C 74% C
Average Annual (5 Year Horizon)  
Capital Gain 105.69% 89% B+ 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 105.69% 89% B+ 94% A
Risk Return Profile  
Volatility (Standard Deviation) 232.24% 10% F 6% F
Risk Adjusted Return 45.51% 64% D 64% D
Market Capitalization 0.02B 6% F 4% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 21.61 59% F 41% F
Price/Book Ratio 2.23 69% D+ 52% F
Price / Cash Flow Ratio -4.84 52% F 67% D+
EV/EBITDA 14.78 62% D- 46% F
Management Effectiveness  
Return on Equity 9.35% 85% B 66% D
Return on Invested Capital -5.01% 61% D- 37% F
Return on Assets -4.57% 65% D 35% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.12 99% A+ 95% A
Short Percent 5.15% 37% F 32% F
Beta -5.09 100% A+ 100% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector